Roberto Salgado, MD, anatomic pathologist for breast cancer translational research at Institut Jules Bordet, examines the significance of tumor-infiltrating lymphocytes (TILs) in various breast cancer ...
About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.
Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...
Raez, MD, discusses the current liquid biopsy options for patients with lung cancer through ... That's the most important thing because, as I said, if you have 100 patients with lung cancer, breast ...
3 They evaluated plasma samples using untargeted ultrahigh-performance liquid chromatography ... follow-up or biopsy, raising ...
Enhertu maintained HRQOL and neurological function in HER2-positive metastatic breast cancer patients, regardless of brain ...
BioView Ltd. , a company developing advanced medical imaging systems for cancer cell detection, traded on the Tel Aviv Stock Exchange, today announced the completion of the first stage of its joint ...
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR ...
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either ...
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or ...
WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUM. Independent findings support ANGLE's HER2 assay development programme. Potential fo ...
An announcement from ANGLE plc ( (GB:AGL) ) is now available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback